Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 KEYNOTE-426 Study

Plimack, Elizabeth R.; Powles, Thomas; Stus, Viktor; Gafanov, Rustem; Nosov, Dmitry; Waddell, Tom; Alekseev, Boris; Pouliot, Frederic; Melichar, Bohuslav; Soulieres, Denis; Borchiellini, Delphine; Mcdermott, Raymond S.; Vynnychenko, Ihor; Chang, Yen-Hwa; Tamada, Satoshi; Atkins, Michael B.; Li, Chenxiang; Perini, Rodolfo; Molife, L. Rhoda; Bedke, Jens; Rini, Brian I.

Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 KEYNOTE-426 Study

Autor(en):

Plimack, Elizabeth R.; Powles, Thomas; Stus, Viktor; Gafanov, Rustem; Nosov, Dmitry; Waddell, Tom; Alekseev, Boris; Pouliot, Frederic; Melichar, Bohuslav; Soulieres, Denis; Borchiellini, Delphine; Mcdermott, Raymond S.; Vynnychenko, Ihor; Chang, Yen-Hwa; Tamada, Satoshi; Atkins, Michael B.; Li, Chenxiang; Perini, Rodolfo; Molife, L. Rhoda; Bedke, Jens; Rini, Brian I.

Tübinger Autor(en):

Bedke, Jens

Erschienen in:

European Urology (2023), Bd. 84, H. 5, S. 449-454

Verlagsangabe:

Amsterdam : Elsevier

Sprache:

Englisch

Referenz zum Volltext:

http://dx.doi.org/10.1016/j.eururo.2023.06.006

ISSN:

0302-2838